BNTX stock is climbing on Monday after BioNTech reported better-than-expected results. The company credits Covid-19 vaccine ...
COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering ...
Q1 2022 Earnings Conference Call May 09, 2022, 08:00 ET Company Participants Sylke Maas - VP, IR and Business Strategy Ugur Sahin - Co-Founder & ...
First quarter revenues of €6.4 billion 1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.97 2) Reiterates BioNTech COVID-19 2022 vaccine reve ...
Revenues of German vaccine developer BioNTech in the first quarter (Q1) of 2022 more than tripled year-on-year to 6.4 billion euros (6.7 billion U.S. dollars), the company said on Monday. The increase ...
Moderna CEO ... Pfizer/BioNTech, which make messenger RNA vaccines that can be updated somewhat quicker than those from competitors, said they are developing vaccines targeting the Omicron variant ...
First quarter revenues of €6.4 billion1, net income of €3.7 billion and fully diluted earnings per share of €14.24 ($15.972)Reiterates BioNTech COVID-19 2022 vaccine revenue guidance of € ...
"During the first quarter, we demonstrated continued execution across our growth pillars in addressing infectious diseases and oncology," said Ugur Sahin, M.D., CEO ... BioNTech and Pfizer are ...